Cyamemazine


Concise Prescribing Info
Indications/Uses
Psychoses.
Dosage/Direction for Use
Adult: PO 25-600 mg/day in 2-3 divided doses. IM 25-200 mg/day.
Contraindications
Coma, CNS depression and phaeochromocytoma.
Special Precautions
Renal and hepatic impairment, CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, prostatic hypertrophy, elderly, history of angle-closure glaucoma, severe respiratory disease, blood dyscrasias or history of jaundice. Photosensitisation may occur. May affect performance of skilled tasks. Gradual withdrawal after long-term therapy and monitor closely to avoid risk of acute withdrawal syndromes or rapid relapse. Pregnancy, lactation.
Adverse Reactions
Parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia. Interference with temp regulation. CNS effects, GI disturbances, nasal congestion, antimuscarinic symptoms, CV symptoms, ECG changes, endocrine effects, blood dyscrasias, photosensitisation, contact sensitisation and rashes, jaundice, corneal and lens opacities, purplish pigmentation of the skin, cornea, conjunctiva and retina.
Potentially Fatal: Neuroleptic malignant syndrome.
Drug Interactions
Increased risk of extrapyramidal adverse effects when used with SSRIs. May cause neuroleptic malignant syndrome or hyperpyrexia when used with chlorpromazine, levomepromazine or trifluoperazine.
CIMS Class
ATC Classification
N05AA06 - cyamemazine ; Belongs to the class of phenothiazine antipsychotics with aliphatic side-chain.
Disclaimer: This information is independently developed by CIMS based on cyamemazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in